GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » PS Ratio

InnoCare Pharma (HKSE:09969) PS Ratio : 13.64 (As of May. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InnoCare Pharma's share price is HK$4.57. InnoCare Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.34. Hence, InnoCare Pharma's PS Ratio for today is 13.64.

Good Sign:

InnoCare Pharma Ltd stock PS Ratio (=9.54) is close to 5-year low of 9.54

The historical rank and industry rank for InnoCare Pharma's PS Ratio or its related term are showing as below:

HKSE:09969' s PS Ratio Range Over the Past 10 Years
Min: 13.64   Med: 11360   Max: 30400
Current: 13.64

During the past 7 years, InnoCare Pharma's highest PS Ratio was 30400.00. The lowest was 13.64. And the median was 11360.00.

HKSE:09969's PS Ratio is ranked worse than
58.36% of 999 companies
in the Biotechnology industry
Industry Median: 9.3 vs HKSE:09969: 13.64

InnoCare Pharma's Revenue per Sharefor the three months ended in Dec. 2023 was HK$0.14. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.34.

Warning Sign:

InnoCare Pharma Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of InnoCare Pharma was 1.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 521.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 388.00% per year.

During the past 7 years, InnoCare Pharma's highest 3-Year average Revenue per Share Growth Rate was 877.80% per year. The lowest was 521.00% per year. And the median was 678.60% per year.

Back to Basics: PS Ratio


InnoCare Pharma PS Ratio Historical Data

The historical data trend for InnoCare Pharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma PS Ratio Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - 6,820.00 16.36 28.90 14.38

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.90 25.58 27.17 14.38 -

Competitive Comparison of InnoCare Pharma's PS Ratio

For the Biotechnology subindustry, InnoCare Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's PS Ratio falls into.



InnoCare Pharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

InnoCare Pharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=4.57/0.335
=13.64

InnoCare Pharma's Share Price of today is HK$4.57.
InnoCare Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


InnoCare Pharma  (HKSE:09969) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


InnoCare Pharma PS Ratio Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (HKSE:09969) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
King Bridge Investments Limited 2101 Beneficial owner
Pang Kee Chan Hebert 2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Cui Jisong
Hhlr Fund, L.p. 2101 Beneficial owner
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Tmf (cayman) Ltd. 2301 Trustee
Sunland Biomed Ltd 2101 Beneficial owner

InnoCare Pharma (HKSE:09969) Headlines

No Headlines